Abstract
Cancer is a diverse class of diseases which differ widely in their cause and biology. The aberrant behavior of cancer reflects up regulation of certain oncogenic signaling pathways that promote proliferation, inhibit apoptosis, and enable the cancer to spread and evoke angiogenesis. Phosphoinositide-3-kinase(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway controls various biological processes that are important for normal functioning of the cell via cell cycle progression, survival, migration, transcription, translation and metabolism. However, PI3K signaling pathway is dysregulated almost in all cancers which is due to the amplification and genetic mutation of PI3K gene, encoding catalytic and regulatory subunit of PI3K isoforms. The current review focuses on the structural features of various PI3K isoforms including Akt and mTOR and their inhibition using specific small molecule inhibitors in an attempt to achieve an attractive target for cancer prevention and chemotherapy.
Keywords: Anticancer target, cancer, inhibitors, PI3K-Akt-mTOR, Signaling, therapy, translation.
Anti-Cancer Agents in Medicinal Chemistry
Title:Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Volume: 13 Issue: 10
Author(s): Asif Khurshid Qazi, Aashiq Hussain, Abid Hamid, Yasrib Qurishi, Rabiya Majeed, Mudassier Ahmad, Rauf Ahmad Najar, Javeed Ahmad Bhat, Shashank Kumar Singh, Mohmmad Afzal Zargar, Shakir Ali and Ajit Kumar Saxena
Affiliation:
Keywords: Anticancer target, cancer, inhibitors, PI3K-Akt-mTOR, Signaling, therapy, translation.
Abstract: Cancer is a diverse class of diseases which differ widely in their cause and biology. The aberrant behavior of cancer reflects up regulation of certain oncogenic signaling pathways that promote proliferation, inhibit apoptosis, and enable the cancer to spread and evoke angiogenesis. Phosphoinositide-3-kinase(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway controls various biological processes that are important for normal functioning of the cell via cell cycle progression, survival, migration, transcription, translation and metabolism. However, PI3K signaling pathway is dysregulated almost in all cancers which is due to the amplification and genetic mutation of PI3K gene, encoding catalytic and regulatory subunit of PI3K isoforms. The current review focuses on the structural features of various PI3K isoforms including Akt and mTOR and their inhibition using specific small molecule inhibitors in an attempt to achieve an attractive target for cancer prevention and chemotherapy.
Export Options
About this article
Cite this article as:
Qazi Khurshid Asif, Hussain Aashiq, Hamid Abid, Qurishi Yasrib, Majeed Rabiya, Ahmad Mudassier, Najar Ahmad Rauf, Bhat Ahmad Javeed, Singh Kumar Shashank, Zargar Afzal Mohmmad, Ali Shakir and Saxena Kumar Ajit, Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (10) . https://dx.doi.org/10.2174/1871520613666131125123241
DOI https://dx.doi.org/10.2174/1871520613666131125123241 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Current Pharmaceutical Biotechnology Treatment of Chronic Pain with Drugs that Modulate Central Nervous System Serotonin and Norepinephrine
Current Drug Therapy Radiolabeled Compounds in Diagnosis of Infectious and Inflammatory Disease
Current Pharmaceutical Design Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry Tumor Stroma Manipulation By MSC
Current Drug Targets Teratogenic Toxicity Evaluation of Bladder Cancer-Specific Oncolytic Adenovirus on Mice
Current Gene Therapy Chemoprevention of Colorectal Carcinogenesis by Natural Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Chemoresistance in High-Grade Gliomas: Relevance of Adenosine Signalling in Stem-Like Cells of Glioblastoma Multiforme
Current Drug Targets TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy
Current Topics in Medicinal Chemistry Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation
Current Drug Metabolism Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Analysis of miRNAs Targeting 3’UTR of H2AFX Gene: a General <i>in Silico</i> Approach
MicroRNA Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets
Current Medicinal Chemistry Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets Clinical Impacts of Juxtapapillary Duodenal Diverticulum Detected on Computed Tomography
Current Medical Imaging Lung Cancer: Are we up to the Challenge?
Current Genomics EGFR(s) in Aging and Carcinogenesis of the Gastrointestinal Tract
Current Protein & Peptide Science Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy